New painkiller could cut opioid use after knee surgery
NCT ID NCT07430085
First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times
Summary
This study tests whether a long-acting painkiller (bupivacaine-meloxicam) can reduce pain and the need for opioid medications after robot-assisted knee replacement. 150 adults with knee osteoarthritis will receive either the new painkiller or a standard injection. Researchers will measure pain levels and opioid use for 72 hours after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bupivacaine-meloxicam extended-release solution
- What this could lead to
- If it works, this could offer a better way to manage pain after knee replacement, reducing the need for opioids.
- What could go wrong
- This is a small, early-phase study (Phase 4) with only 150 participants. The results may not apply to everyone, and there is a risk of side effects like allergic reactions or kidney problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KNEE ARTHROPLASTY, TOTAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ear cartilage to the rescue? a tiny biopsy could rebuild knees
- Which knee surgery approach gets you back on your feet faster?
- Can a lotion outperform standard gel for knee pain?
- A digital coach for knee replacement recovery — can it boost satisfaction and exercise?
- Virtual program aims to keep joint replacement patients moving while they wait
- Cheaper collagen injection could rival standard knee OA treatment